Forest Labs, Merz Pharma Have $54 Million Namenda Antitrust Deal

AbbVie Inc. and Merz Holding Gmbh & Co. affiliates will pay $54.4 million to end antitrust litigation over their alleged scheme to delay generic versions of the Alzheimer’s disease treatment Namenda, according to federal court filings in Manhattan.

Judge Colleen McMahon signed off tentatively Monday on the agreement to resolve class action claims facing AbbVie unit Forest Laboratories and a Merz subsidiary in the US District Court for the Southern District of New York. She scheduled a final settlement hearing for March 13.

The ruling came two days after the pact’s terms were made public Nov. 12, when the pension ...